![]() |
市场调查报告书
商品编码
1731741
2026 年至 2032 年人工肾臟市场(按设备类型、最终用户、透析和地区划分)Artificial Kidney Market By Device Type (Wearable Artificial Kidney, Implantable Artificial Kidney), By End-user (Hospitals, Specialty Clinics), By Dialysis (Hemodialysis and Peritoneal Dialysis), And Region for 2026-2032 |
需要透析的患者数量不断增加,肾臟替代疗法的技术进步,例如穿戴式和可植入的人工肾臟,也正在推动市场创新。 2024年人工肾臟的需求将超过664.9亿美元,到2032年将达到6,055亿美元。
此外,人们对肾臟移植益处的认识不断提高以及新兴国家医疗保健基础设施的不断扩大也促进了市场扩张。这些因素推动了各行业人工肾臟使用量的增加,预计从 2026 年到 2032 年,人工肾臟的复合年增长率将达到 35.08%。
人工肾臟市场定义/概述
人工肾臟,也称为透析机,是一种执行天然医疗设备基本功能的医疗设备,例如过滤血液中的废物和多余的液体,维持体内电解质平衡,以及防止毒素积聚。其主要用于治疗慢性肾臟病和急性肾衰竭,为无法接受肾臟移植的患者提供维持生命的肾臟替代疗法。未来,生物技术和奈米技术的进步有望推动更高效、更便携的人工肾臟的开发,从而可能带来生物工程器官和提供持续透析治疗的可穿戴设备等创新。
慢性肾臟病(CKD) 盛行率的上升和对具有成本效益的治疗方案的需求的不断增长正在极大地推动人工肾臟市场的发展。根据美国疾病管制与预防中心 (CDC) 的数据,美国约有 3,700 万成年人患有 CKD,另有数百万人面临患病风险。随着医疗保健领域转向基于价值的护理,医疗保健提供者越来越多地寻求可负担的解决方案,使他们能够提供有效的治疗,而无需承担肾臟移植和长期住院的高昂费用。
此外,肾臟疾病的经济负担也增加了对更容易获得的治疗方法的需求。根据美国糖尿病、消化和肾臟疾病研究所 (NIDDK) 的报告,末期肾功能衰竭(ESRD) 患者每年的透析费用每人可超过 90,000 美元,这对患者和医疗保健系统来说都是沉重的经济负担。因此,旨在降低治疗成本和提高效率的人工肾臟技术创新对于满足日益增长的经济实惠的医疗保健解决方案的需求同时改善患者的治疗效果至关重要。
资料安全和隐私问题对人工肾臟市场的成长构成了重大挑战,尤其是在技术进步导致数位健康解决方案与医疗设备结合的情况下。人工肾臟,尤其是连接到远端医疗平台和监控系统的人工肾臟,会收集和传输敏感的患者讯息,包括健康数据和治疗历史。医疗保健领域网路攻击和资料外洩事件日益频繁,引发了人们对这些资讯可能被滥用的担忧,使得患者和服务提供者不愿采用这些创新解决方案。
此外,美国的《健康保险互通性与课责法案》(HIPAA)等严格的资料保护法规要求製造商在安全技术和合规措施方面进行大量投资。这些复杂性和额外成本可能会减缓人工肾臟的开发和广泛应用,尤其是对于中小型企业而言。由于患者信任在医疗保健中至关重要,透过强有力的资料保护措施和透明的做法解决这些安全问题对于建立对人工肾臟技术的信任和确保持续的市场成长至关重要。
The increasing number of patients requiring dialysis. Technological advancements in kidney replacement therapies, such as wearable and implantable artificial kidneys, are also driving innovation in the market. The need for artificial kidney is surpassing USD 66.49 Billion in 2024 and reaching USD 605.5 Billion by 2032.
Additionally, the growing awareness of the benefits of kidney transplantation and the expanding healthcare infrastructure in emerging economies contribute to market expansion. These factors contribute to the increasing use of artificial kidney in a variety of industries is expected to grow at a CAGR of 35.08% about from 2026 to 2032.
Artificial Kidney Market: Definition/ Overview
An artificial kidney, also known as a dialysis machine, is a medical device that performs the essential functions of a natural kidney by filtering waste products and excess fluids from the blood, thereby maintaining the body's electrolyte balance and preventing the accumulation of toxins. Its primary application is in the treatment of individuals with chronic kidney disease or acute kidney injury, providing life-sustaining renal replacement therapy for patients who cannot undergo kidney transplantation. Looking to the future, advancements in biotechnology and nanotechnology hold promise for the development of more efficient and portable artificial kidneys, potentially leading to innovations such as bioengineered organs and wearable devices that offer continuous dialysis treatment, significantly enhancing patients' quality of life and reducing the need for traditional dialysis sessions.
The increasing prevalence of chronic kidney disease (CKD) and the growing demand for cost-effective treatment options are significantly propelling the artificial kidney market. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million adults in the United States have CKD, and millions more are at risk. As the healthcare landscape shifts towards value-based care, healthcare providers are increasingly seeking affordable solutions that can deliver effective treatment without the high costs associated with kidney transplants or prolonged hospital stays.
Furthermore, the economic burden of kidney diseases necessitates the need for more accessible treatment options. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reported that the annual cost of dialysis for patients with end-stage renal disease (ESRD) can exceed $90,000 per patient, underscoring the financial strain on both patients and healthcare systems. As a result, innovations in artificial kidney technologies, aimed at reducing treatment costs and enhancing efficiency, are essential to meet the rising demand for affordable healthcare solutions while improving patient outcomes.
Data security and privacy concerns pose significant challenges to the growth of the artificial kidney market, particularly as advancements in technology integrate digital health solutions with medical devices. Artificial kidneys, especially those connected to telemedicine platforms or monitoring systems, collect and transmit sensitive patient information, including health data and treatment history. The increasing frequency of cyberattacks and data breaches in healthcare raises alarms about the potential misuse of this information, which can deter patients and healthcare providers from adopting these innovative solutions.
Moreover, stringent regulations regarding data protection, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States, require manufacturers to invest heavily in secure technology and compliance measures. This added layer of complexity and cost can slow down the development and deployment of artificial kidneys, particularly for smaller companies. As patient trust is paramount in healthcare, addressing these security concerns through robust data protection measures and transparent practices will be crucial for fostering confidence in artificial kidney technologies and ensuring sustained market growth.
The rising adoption of wearable devices is expected to significantly boost the artificial kidney market by enhancing patient engagement and facilitating remote monitoring of kidney health. Wearable technologies, such as smartwatches and health trackers, are increasingly being integrated with advanced monitoring systems that can provide real-time data on vital signs, fluid balance, and kidney function. This integration empowers patients to take an active role in managing their health, leading to timely interventions and improved outcomes.
Moreover, the growing trend of telemedicine and remote patient monitoring is driving demand for wearable artificial kidneys, as healthcare providers seek efficient ways to manage chronic conditions without the need for frequent hospital visits.
The implantable artificial kidney segment is the fastest-growing segment, driven by advancements in bioengineering and materials science that aim to create devices capable of mimicking natural kidney functions more effectively.
The widespread availability of advanced technologies in hospitals is significantly fueling the artificial kidney market by enhancing the efficiency and effectiveness of renal care. Innovations such as portable dialysis machines, automated systems, and remote monitoring capabilities are making it easier for healthcare providers to deliver high-quality care.
These advancements enable hospitals to offer more comprehensive treatment options, reducing the need for patients to seek alternatives, which in turn drives demand for artificial kidneys. Moreover, the integration of artificial intelligence and data analytics into renal care is improving patient outcomes through personalized treatment plans and real-time monitoring of patient health.
Specialty Clinics is the fastest-growing segment, driven by the increasing trend towards outpatient care and the desire for more personalized treatment options.
Country/Region-wise
Technological advancements in North America are poised to significantly drive the expansion of the artificial kidney market. Innovations such as miniaturization of dialysis devices, the integration of artificial intelligence for personalized treatment, and the development of wearable dialysis systems are enhancing the accessibility and efficiency of renal replacement therapies. According to the U.S. Renal Data System, as of 2021, over 786,000 individuals were undergoing dialysis in the United States, and advancements in technology could help meet the growing demand for more effective and convenient treatment options.
Moreover, the increasing investment in research and development, alongside supportive government initiatives, is further propelling market growth. The National Institutes of Health (NIH) reported funding of approximately $690 million in 2022 for kidney disease research, which aims to foster innovations in artificial kidneys and improve patient outcomes. Such financial backing, combined with the rising prevalence of chronic kidney disease-projected to affect about 37 million adults in the U.S. by 2030-underscores the vital role of technological progress in shaping the future of the artificial kidney market.
The increasing number of well-equipped hospitals in the Asia Pacific region is expected to significantly propel the artificial kidney market. As healthcare infrastructure improves, more hospitals are investing in advanced medical technologies, including dialysis machines and artificial kidney devices. According to the World Bank, the number of hospitals in the Asia Pacific region has grown by approximately 20% from 2010 to 2020, reflecting the region's commitment to enhancing healthcare services. This growth not only increases access to treatment for patients with chronic kidney disease but also encourages the adoption of advanced dialysis technologies, thereby expanding the artificial kidney market.
Furthermore, government initiatives aimed at improving healthcare access and the growing prevalence of kidney-related disorders are driving demand for artificial kidneys. The Asia Pacific region accounted for nearly 50% of global end-stage renal disease cases in 2021, as reported by the Global Burden of Disease Study. With an aging population and lifestyle-related health issues on the rise, the need for artificial kidneys is expected to surge. Coupled with the expanding hospital infrastructure, this demand presents a lucrative opportunity for manufacturers and healthcare providers, reinforcing the positive outlook for the artificial kidney market in the region.
The competitive landscape of the artificial kidney market is characterized by a mix of established players and emerging startups, each focusing on innovative features such as real-time tracking, integration with IoT devices, and user-friendly interfaces. Companies are increasingly investing in research and development to enhance product offerings and improve customer service, creating a dynamic and rapidly evolving market environment.
Some of the prominent players operating in the artificial kidney market include:
Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., DaVita Inc., NIPRO Medical Corporation, Nikkiso Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Baxter, Merit Medical Systems, Medtronic, Xcorporeal, Inc.
In August 2024 Reistone Biopharma reported significant progress in its clinical trials for an innovative artificial kidney that utilizes bioengineered materials to mimic natural kidney function. Preliminary results have shown promising outcomes in terms of biocompatibility and efficacy, paving the way for future regulatory approvals. The company aims to revolutionize renal replacement therapy by providing a more efficient and long-lasting solution for patients with chronic kidney disease.
In July 2024 Dialyze Direct announced the expansion of its home dialysis services, integrating artificial kidney technology into their offerings. This initiative aims to provide patients with greater flexibility and comfort by enabling them to manage their treatment at home. The company is focused on enhancing patient education and support to ensure successful adoption of these advanced technologies in home settings.
In June 2024 Xeltis unveiled groundbreaking results from its research on bioengineered kidneys, which utilize a unique combination of synthetic and biological materials to promote kidney regeneration. The company's innovative approach aims to create a functional artificial kidney that not only replaces lost function but also encourages tissue regeneration.